title: Immunoengineering: how nanotechnology can enhance cancer immunotherapy.
abstract: Although cancer immunotherapy can lead to durable outcomes, the percentage of patients who respond to this disruptive approach remains modest to date. Encouragingly, nanotechnology can enhance the efficacy of immunostimulatory small molecules and biologics by altering their co-localization, biodistribution, and release kinetics.
authors: Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address: michael_goldberg1@dfci.harvard.edu.
authors: Michael S
authors: MS
authors: Goldberg
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D003713:Dendritic Cells / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D036103:Nanotechnology; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D019496:Cancer Vaccines